ADVBHealthcare · Diagnostics & ResearchADVB Stock Forecast: Advanced Biomed, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 14 of 100 as at 19 Sept 2026 — in the weakest quartile.
ADVB stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Advanced Biomed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ADVB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ADVB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ADVB appears on the weeks it earns a place.
ADVB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Advanced Biomed, Inc. returned −41.9% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ADVB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Advanced Biomed, Inc. (ADVB) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.6×
- Price / sales
- —
- Price / book
- 1.0×
- EV / EBITDA
- −2.4×
Cheaper than 70% of US stocks
Cheaper than 73% of US stocks
Cheaper than 73% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 71.3%
- Return on assets
- −21.5%
- Dividend yield
- —
Higher than 95% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Advanced Biomed, Inc. (ADVB) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Advanced Biomed, Inc. has a market value of $10.8M and an enterprise value of $7.1M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: $4.6M.
Diluted earnings per share, trailing twelve months: $4.02.
Free cash flow in the twelve months to 31 Mar 2026: −$4.8M, after $18K of capital spending.
Trailing P/E: 1.6×.
Advanced Biomed, Inc. employs 31 people.
Data provided by Twelve Data
ADVB vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Advanced Biomed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ADVB stock
How does Ticker Nerd's model rank ADVB?
As at 19 Sept 2026, Advanced Biomed, Inc. ranks 14 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
What is the ADVB stock forecast for 2030?
No analyst covering Advanced Biomed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ADVB are extrapolating price history, which says nothing about the business.
How has ADVB stock performed over the past year?
Advanced Biomed, Inc. returned -41.9% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Advanced Biomed, Inc. do?
Advanced Biomed Inc. is a medical technology holding company focused on microfluidic biochip technologies for cancer diagnostics and precision oncology.
About Advanced Biomed, Inc.
Advanced Biomed Inc. is a medical technology holding company focused on microfluidic biochip technologies for cancer diagnostics and precision oncology. The company develops assay products and laboratory solutions used in early screening, detection, diagnosis, staging, and treatment support for cancer patients. Its product portfolio includes automated sample preparation systems, circulating tumor cell capture devices, rare cell analysis tools, immunostaining kits, and lung cancer early screening kits. Advanced Biomed Inc. also provides related biochips and analyzer systems that combine semiconductor technology with biotechnology to support clinical and research workflows. The company serves healthcare and diagnostic applications across Taiwan and other markets, with an emphasis on improving the accuracy and efficiency of oncology testing. Headquartered in Tainan, Taiwan, Advanced Biomed Inc. operates as a specialized player in the healthcare and biotechnology sector.
CEO Mr. Xiaomin Chen Ph.D. · 31 employees · United States · https://www.advanbiomed.com